Proteomic analysis of coronary sinus serum reveals leucine-rich alpha2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure.
AuthorsWatson, Chris J
Ledwidge, Mark T
Byrne, Jennifer C
Dunn, Michael J
McDonald, Kenneth M
Baugh, John A
AffiliationSchool of Medicine and Medical Science, St Vincent's University Hospital and The , Conway Institute of Biomolecular and Biomedical Research, University College, Dublin, Ireland.
Electrophoresis, Gel, Two-Dimensional
Enzyme-Linked Immunosorbent Assay
Natriuretic Peptide, Brain/blood
Receptors, Transforming Growth Factor beta/analysis
Tumor Necrosis Factor-alpha/blood
Ventricular Dysfunction, Left/*blood/diagnosis/etiology
MetadataShow full item record
CitationCirc Heart Fail. 2011 Mar;4(2):188-97. Epub 2011 Jan 31.
JournalCirculation. Heart failure
AbstractBACKGROUND: Heart failure (HF) prevention strategies require biomarkers that identify disease manifestation. Increases in B-type natriuretic peptide (BNP) correlate with increased risk of cardiovascular events and HF development. We hypothesize that coronary sinus serum from a high BNP hypertensive population reflects an active pathological process and can be used for biomarker exploration. Our aim was to discover differentially expressed disease-associated proteins that identify patients with ventricular dysfunction and HF. METHODS AND RESULTS: Coronary sinus serum from 11 asymptomatic, hypertensive patients underwent quantitative differential protein expression analysis by 2-dimensional difference gel electrophoresis. Proteins were identified using mass spectrometry and then studied by enzyme-linked immunosorbent assay in sera from 40 asymptomatic, hypertensive patients and 105 patients across the spectrum of ventricular dysfunction (32 asymptomatic left ventricular diastolic dysfunction, 26 diastolic HF, and 47 systolic HF patients). Leucine-rich alpha2-glycoprotein (LRG) was consistently overexpressed in high BNP serum. LRG levels correlate significantly with BNP in hypertensive, asymptomatic left ventricular diastolic dysfunction, diastolic HF, and systolic HF patient groups (P
- Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?
- Authors: Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, Martos R, Baugh JA, Ledwidge MT, McDonald KM
- Issue date: 2011 Oct
- [Screening for asymptomatic left ventricular systolic dysfunction in high-risk patients. Preliminary experience with a program based on the use of ECG and natriuretic peptide].
- Authors: Tarantini L, Cioffi G, Di Lenarda A, Valle R, Pulignano G, Del Sindaco D, Frigo G, Soravia G, Tessier R, Catania G
- Issue date: 2008 Dec
- Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population.
- Authors: Lam CS, Burnett JC Jr, Costello-Boerrigter L, Rodeheffer RJ, Redfield MM
- Issue date: 2007 Mar 20
- Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF.
- Authors: Takami Y, Horio T, Iwashima Y, Takiuchi S, Kamide K, Yoshihara F, Nakamura S, Nakahama H, Inenaga T, Kangawa K, Kawano Y
- Issue date: 2004 Sep
- Adiponectin in outpatients with coronary artery disease: independent predictors and relationship with heart failure.
- Authors: Baldasseroni S, Mannucci E, Orso F, Di Serio C, Pratesi A, Bartoli N, Marella GA, Colombi C, Foschini A, Valoti P, Mossello E, Fumagalli S, Marchionni N, Tarantini F
- Issue date: 2012 Mar